Previous close | 0.8770 |
Open | 0.8840 |
Bid | 0.9123 x 200 |
Ask | 0.9230 x 200 |
Day's range | 0.8692 - 0.9289 |
52-week range | 0.6500 - 1.4900 |
Volume | |
Avg. volume | 1,486,559 |
Market cap | 369.608M |
Beta (5Y monthly) | 2.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.08 |
Revenue Declines Amidst Generic Competition, Yet Strategic Initiatives Show Promise
-- New VAZKEPA® Patent Issued by European Patent Office Extends Intellectual Property Protection in Europe Until 2039 -- -- In Europe, ~35% Revenue Growth, ~65% In-Market Sales Growth Q1 ‘24 versus Q4 ‘23 Driven by Spain and the UK-- -- Current Cash Position of $308 Million; Remains Stable Over Seven Quarters -- -- Share Repurchase Program of up to $50 Million Approved by Shareholders; Repurchases Expected to Commence Following UK High Court Approval in Second Quarter 2024 -- -- Company to Host
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced its support for a petition filed with the U.S. Food and Drug Administration (FDA) requesting that the Commissioner focus on and take further action to address significant off-label prescribing of fe